Actively Recruiting
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Led by Shandong Boan Biotechnology Co., Ltd · Updated on 2025-06-06
167
Participants Needed
1
Research Sites
120 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid malignancies. The study includes a dose-escalation phase (Part A) and a dose-expansion phase (Part B).
CONDITIONS
Official Title
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Metastatic or unresectable solid malignancy confirmed by tissue testing, with progression after or intolerance to standard therapy or no standard therapy available
- For Part A: advanced malignant solid tumors
- For Part B: metastatic melanoma, advanced breast cancer, advanced non-small cell lung cancer, or advanced pancreatic adenocarcinoma
- Ability to provide adequate tumor tissue for biomarker analysis
- ECOG Performance Status of 0 or 1
- Measurable disease according to RECIST v1.1 criteria
You will not qualify if you...
- Malignant disease within 5 years before first dose, except certain completely resected skin cancers and carcinoma in situ
- Received chemotherapy, radiotherapy, targeted therapy, cell therapy, immunotherapy, ADC medication, or other anti-cancer treatment within 28 days before first dose
- History of severe allergic reactions to any study drug ingredients
- Pregnant or lactating women
- Any medical condition that may prevent safe participation or affect study compliance or result interpretation according to investigator judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, China
Actively Recruiting
Research Team
P
primary investigator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here